Exelixis Inc Stock Price, News & Analysis

Exelixis announced initial results from the JEWEL-101 phase 1 study of XB002, a next-generation tissue factor-targeting antibody-drug conjugate. Presented at a recent symposium, XB002 was well-tolerated, with pharmacokinetic analysis indicating stability and low free payload levels. A total of 19 patients were enrolled at escalating doses, with no dose-limiting toxicities reported. The study aims to evaluate XB002's efficacy in patients with advanced solid tumors, with a particular focus on those with limited treatment options.

Exelixis, Inc. (Nasdaq: EXEL) will release its third quarter 2022 financial results on November 1, 2022, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a business update. Access to the event will be available on the company’s website. Exelixis focuses on developing new cancer therapies, with products like CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO. The company aims to maximize its pipeline potential through ongoing investments and partnerships.

Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.

Exelixis announced promising results from the dose-escalation phase of the STELLAR-001 trial, evaluating XL092 as a treatment for advanced solid tumors. The trial showed that XL092 alone and in combination with atezolizumab displayed manageable safety profiles and preliminary clinical activity, especially in heavily pretreated renal cell carcinoma patients. Notably, tumor reduction was observed in 71% of single-agent XL092 patients. The next step involves expanding the trial using the recommended dose of 100 mg across various solid tumors.

Exelixis announced positive results from the COSMIC-313 trial, evaluating cabozantinib in combination with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC). The trial demonstrated a significant reduction in disease progression or death, achieving a hazard ratio of 0.73. Median progression-free survival was not yet reached with the triplet therapy versus 11.3 months for the dual therapy. However, no significant overall survival benefit was noted at interim analysis, prompting continuation for further analysis. The safety profile was consistent with known drug effects.

Exelixis, Inc. (Nasdaq: EXEL) will participate in investor conferences in September. The company is scheduled to present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:05 p.m. ET in New York City, and at the BofA Securities Global Healthcare Conference on September 15, 2022, at 2:10 p.m. BST in London. Webcast access is available on the Exelixis website, with replays provided for 30 days. Exelixis focuses on oncology and has four commercially available products to address difficult-to-treat cancers.

Exelixis reported total revenues of $419.4 million for Q2 2022, marking a 9% increase from $385.2 million in Q2 2021. The cabozantinib franchise generated $347.0 million in revenues, reflecting a 22% year-over-year growth. GAAP diluted EPS was $0.22, while non-GAAP diluted EPS was $0.28. Research and development expenses rose to $199.5 million, up from $148.8 million in the prior year. Exelixis maintains its 2022 revenue guidance of $1.525 billion to $1.625 billion.

Exelixis, Inc. (Nasdaq: EXEL) will release its Q2 2022 financial results on August 9, 2022, post-market close. A conference call is scheduled for 5:00 p.m. ET to discuss the results and provide a business update. Investors can access the event via Exelixis’s website. The company, founded in 1994, is focused on developing new cancer therapies, with four products currently marketed. Exelixis is a member of the S&P MidCap 400 index, reflecting its status as a profitable mid-sized company.

Exelixis reported that its COSMIC-313 trial met its primary endpoint, showing a significant improvement in progression-free survival (PFS) for patients with advanced kidney cancer when treated with cabozantinib, nivolumab, and ipilimumab. However, the secondary endpoint of overall survival (OS) did not demonstrate a significant benefit, prompting further analysis. Exelixis plans to consult with the FDA regarding a potential regulatory submission. The trial, involving 855 patients, will continue until the next OS analysis.